Synthesis, Structure–Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists
- 15 May 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (11) , 4993-5008
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder which has a higher prevalence and incidence in people older than 60 years. The need for improved AD therapies is unmet as the current therapies are symptomatic with modest efficacy. The 5-HT4 receptor (5-HT4R) partial agonists offer both symptomatic and disease modifying treatment as they shift amyloid precursor protein (APP) processing from amyloidogenic to non-amyloidogenic pathway by activating α-secretase enzyme. In addition, they also offer symptomatic treatment by increasing neurotransmitter acetylcholine levels in the brain. Fascinated by dual mechanism of action, several chemical scaffolds having 5-HT4R pharmacophore were designed and evaluated. Most of the synthesized compounds showed potent in vitro affinities and in vivo efficacies. Upon focused structure activity relationships, compound 4o was identified as potent 5-HT4R partial agonist with favorable ADME properties and good in vivo efficacy. GR-125487, a selective 5-HT4R antagonist attenuated the activity of compound 4o in cognition model NORT.Keywords
This publication has 38 references indexed in Scilit:
- Oxadiazoles in Medicinal ChemistryJournal of Medicinal Chemistry, 2012
- The novel object recognition memory: neurobiology, test procedure, and its modificationsCognitive Processing, 2011
- Synopsis of Some Recent Tactical Application of Bioisosteres in Drug DesignJournal of Medicinal Chemistry, 2011
- 5-HT4 receptors, a place in the sun: act twoCurrent Opinion in Pharmacology, 2011
- Distinct Functional Effects of Human 5-HT4 Receptor Isoforms on β-Amyloid SecretionNeurodegenerative Diseases, 2008
- VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine effluxNeuropharmacology, 2007
- 5‐HT4 receptor agonists increase sAPPα levels in the cortex and hippocampus of male C57BL/6j miceBritish Journal of Pharmacology, 2007
- Pharmacological Evidence for a Functional Serotonin-2B Receptor in a Human Uterine Smooth Muscle Cell LineThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Drugs Acting on Serotonin Receptors for the Treatment of Functional GI DisordersDigestive Diseases, 2006
- In Vivo Characterization of Aβ(40) Changes in Brain and Cerebrospinal Fluid Using the Novel γ-Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the RatThe Journal of Pharmacology and Experimental Therapeutics, 2006